Publications

A Novel Small Molecule Nucleoside Analog, RX-3117, Shows Potent Therapeutic Activity in Combination with Nab-paclitaxel and Checkpoint Inhibitors in Xenograft Models

PCS3117

Julie Frank, Young Bok Lee, Deog Joong Kim, Ely Benaim Rexahn Pharmaceuticals, Inc., Rockville, MD

View Publication

Results of a Phase 1 Study of Single Agent RX-3117: An Oral Antimetabolite Nucleoside to Treat Solid Tumors

PCS3117

Drew W. Rasco, Christine Peterson, Reza Mazhari, Ely Benaim and Jaime R. Merchan, South Texas Accelerated Research Therapeutics, San Antonio, TX, 2Rexahn Pharmaceuticals Inc., Rockville, MD, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

View Publication

RX-3117, An Oral Antimetabolite to Treat Advanced Solid Tumors (ST): Phase 1 and Ongoing Phase 2a Results

PCS3117

Drew W. Rasco, Christine Peterson, Reza Mazhari, Ely Benaim and Jaime R. Merchan, South Texas Accelerated Research Therapeutics, San Antonio, TX, Rexahn Pharmaceuticals Inc., Rockville, MD, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

View Publication

RX3117: Activity of an Oral Antimetabolite Nucleoside in Subjects with Pancreatic Cancer – Preliminary Results of Stage II of the Phase Ia/IIb Study

PCS3117

Vincent Chung, Jaime R. Merchan, Allyson J. Ocean, Drew W. Rasco, Hani M. Babiker, Ira Oliff, Ravi Kumar Paluri, Eloy Roman, Julie Poore, Ely Benaim; City of Hope, Duarte, CA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL; 3Weill Cornell Medical College, New York, NY; South Texas Accelerated Research Therapeutics, San Antonio, TX; University of Arizona Cancer Center, Tucson, AZ; 6Orchard Healthcare Research, Inc., Skokie, IL; University of Alabama at Birmingham, Birmingham, AL; Lakes Research, Miami Lakes, FL; Rexahn Pharmaceuticals Inc., Rockville, MD

View Publication

RX 3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Ad van ced Urothelial Cancer ( aUC

PCS3117

Meghan Salgia , Sumanta K. Pal , Vincent M. Chung , Scott T. Tagawa , Joel Picus , Hani M. Babiker , Sumati Gupta , Julie Poore , Christine Peterson , and Ely Benaim ; City of Hope, Duarte, CA; Weill Cornell Medical College, New York, NY; Washington University in St. Louis School of Medicine, St. Louis, MO; 4 University of Arizona Cancer Center, Tucson, AZ; 5 University of Utah Huntsman Cancer Institute, Salt Lake City, UT; 6 Rexahn Pharmaceuticals Inc., Rockville, MD

View Publication

Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker

PCS3117

In vitro models: - A549 and SW1573 non-small cell lung cancer (NSCLC) cell lines - Cells were cultured in DMEM plus 10% fetal bovine serum - A panel of various cell lines with different UCK activity In vivo models: - a panel of cells from various xenografts - 3 xenograft models with different sensitivity to RX-3117 and UCK activity Godefridus J. Peters, Joris R Julsing, Kees Smid, Daniel de Klerk, Dzjemma Sarkisjan, Mi Young Yang, Young Bok Lee, Deog Joong Kim,

View Publication

RX3117, An Oral Antimetabolite Nucleoside Shows Activity in Subjects with Pancreatic Cancer. Preliminary Results of Stage 1 of the Phase 1a/2b Study

PCS3117

Drew W. Rasco, Christine Peterson, Ely Benaim and Jaime R. Merchan. South Texas Accelerated Research Therapeutics, San Antonio, TX, Rexahn Pharmaceuticals Inc., Rockville, MD, 3Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

View Publication

A PHASE 1/2 STUDY OF RX-3117, AN ORAL ANTIMETABOLITE NUCLEOSIDE, IN COMBINATION WITH NAB-PACLITAXEL (NAB-PAC) AS FIRST LINE TREATMENT OF METASTATIC PANCREATIC CANCER (MET-PC): PRELIMINARY RESULTS

PCS3117

Hani M. Babiker, Peter N. Schlegel, Lee G. Hicks, Andrea Bullock, NafisaJ. Burhani, Ely Benaim, Callie Heaton, Christine Peterson6, Allyson J. Ocean7 1University of Arizona Cancer Center, Tucson, AZ, USA; Cancer Care Northwest, Spokane, WA, USA; Baptist Health Lexington, Lexington, KY, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA; Joliet Oncology-Hematology Associates Ltd., Joliet, IL, USA; Rexahn Pharmaceuticals, Inc., Rockville, MD, USA; New York Presbyterian-Weill Cornell Medical Center, New York, NY, USA.

View Publication

RX-3117, A NOVEL, ORAL NUCLEOSIDE ANALOG, IN COMBINATION WITH NAB-PACLITAXEL (NAB-PAC) IN FIRST-LINE METASTATIC PANCREATIC CANCER (MET-PC): SAFETY, TOLERABILITY AND PRELIMINARY RESPONSES

PCS3117

BABIKER H, SCHLEGEL P, BENAIM E, HEATON CM, PETERSON C, OCEAN A University of Arizona Cancer Center, Tucson, AZ, USA; 2 Cancer Care Northwest, Spokane, WA, USA; 3 Rexahn Pharmaceuticals, Inc., Rockville, MD, USA ; 4 New York Presbyterian-Weill Cornell Medical Center, New York, NY, USA

View Publication

Activity of RX-3117, an Oral Antimetabolite Nucleoside, in Subjects with Advanced Urothelial Cancer: Preliminary Results from a Phase IIaStudy

PCS3117

Nicholas Salgia, SumantaK. Pal, Vincent Chung, Scott T. Tagawa, Joel Picus3, Hani M. Babiker4, SumatiGupta5, Raymond Couric Wadlow, Julie Poore, Christine Peterson, Ely Benaim

View Publication